Kiadis Meets With FDA on Reviroc

The FDA has found that data from Dutch drugmaker Kiadis Pharma’s Phase II Reviroc trial is sufficient to support the start of a Phase III study.

In the Phase II trial, treatment with Reviroc demonstrated improved overall survival after autologous bone marrow transplantation in non-Hodgkin’s lymphoma patients. The Phase III trial will focus on patients with large B cell lymphoma, Kiadis said. 

The company expects to file investigational new drug and orphan drug designation applications shortly.